Table 2.

Summary of indications for use of aspirin in pregnancy, shared pathophysiologic mechanisms, and emerging research

	Possible mechanisms	Society recommendations	Selected emerging research topics
Preeclampsia	Inhibits thromboxane production and vasoconstriction → reduces uteroplacental ischemia	ACOG: Low-dose aspirin for women at high risk for PE from 12 to 28 weeks until delivery [74] USPSTF: Low-dose aspirin after 12 weeks for women at high risk for PE [78]	Studies of biomarkers to understand the pathophysiologic benefits of platelet inhibition in PE and prevention of cardiac dysfunction [43, 77]
Preterm delivery		Not recommended in the absence of PE risk factors [74]	Newer trials and meta-analyses suggesting potential benefit [79, 80]
IUGR		Not recommended in the absence of PE risk factors [75]	Clinical models to predict preterm delivery to identify women who might benefit from aspirin [81, 82]

ACOG American College of Obstetricians and Gynecologists, PE preeclampsia, USPSTF United States Preventive Services Task Force, IUGR intrauterine growth restriction